You just read:

KEYTRUDA's Recent Success in Triple-Negative Breast Cancer Validates I-SPY 2 Adaptive Platform Approach to Phase II Clinical Trials

News provided by

Quantum Leap Healthcare Collaborative

Aug 07, 2019, 17:17 ET